Piperacillin/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: A randomized and open-label study

Pediatric Blood and Cancer

Volumn 53, Issue 4, 2009, Pages 610-614

  Uygun, Vedat ^a   Karasu, Gulsun Tezcan ^a   Ogunc, Dilara ^a   Yesilipek, Akif ^a   Hazar, Volkan ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Cefepime; Children; Febrile neutropenia; Piperacillin tazobactam

Indexed keywords

CEFEPIME; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; DRUG DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN TAZOBACTAM COMBINATION PRODUCT; PIPERACILLIN-TAZOBACTAM COMBINATION PRODUCT;

ADOLESCENT; ADULT; ARTICLE; CANCER PATIENT; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; FEVER; INFANT; NEUTROPENIA;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HUMANS; INFANT; MALE; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES;

EID: 69849111017     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22100     Document Type: Article

References (24)

1. Huges WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751. (Pubitemid 34194843)
2. Viscoli C, Castagnola E, Caniggia M, et al. Italian guidelines for the management of infectious complications in pediatric oncology: Empirical antimicrobial therapy of febrile neutropenia. Oncology 1998;55:489-500. (Pubitemid 28396065)
3. Link H, Bohme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients - Guidelines of the Infectious Diseases Working Party (AGHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003;82:S105-S117. (Pubitemid 37265297)
4. Paul M, Soares-Weiser K, Leibovici L. Bata lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: Systemic review and meta-analysis. Br Med J 2003;326:1111-1120. (Pubitemid 36613439)
5. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside containing combinations for empirical antibiotic treatment of febrile neutropenic patients: A meta-analysis. Lancet Infect Dis 2002;2:231-242. (Pubitemid 34464753)
6. Kebudi R, Gorgun O, Ayan I, et al. Randomised comparison of cefepim versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol 2001;36:434-441. (Pubitemid 32240457)
7. Agaoglu L, Devecioglu O, Anak S, et al. Cost-effectiveness of cefepime+netimicin or ceftazidime+amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 2001;13:281-287. (Pubitemid 32575141)
8. Garcia-Rodriguez JA, Gobernado M, Gomis M, et al. Clinical guide for the evaluation and treatment of patients with neutropenia and fever. Rev Esp Quimioter 2001;14:75-83. (Pubitemid 32463554)
9. Saez Llorenz X, McCracken GH. Sepsis syndrome and septic shock in pediatrics: Current concepts of terminology, pathophysiology, and management. J Pediatr 1993;123:497-508.
10. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter related infections. Clin Infect Dis 2001;32:1249-1272. (Pubitemid 32405897)
11. National Cancer Institute Evaluation Program Common Toxicity Criteria. http://ctep.info.nih.gov.
12. Jones RN, Pfaller MA, Fuchus PC, et al. Piperacillin/tazobactam (YTR 830) combination: Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn Microb Infect Dis 1989;12:489-494.
13. Viscoli C, Cometta A, Kern WV, et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 2006;12:212-216. (Pubitemid 43379320)
14. Del FA, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001;33:1295-1301. (Pubitemid 32955177)
15. Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin- tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006;43:447-459. (Pubitemid 44157153)
16. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995;39:445-452.
17. Hamidah A, Rizal AM, Nordiah AJ, et al. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. Singapore Med J 2008;49:26-30. (Pubitemid 351239867)
18. Aksoylar S, Cetingül N, Kantar M, et al. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Pediatr Hematol Oncol 2004;21:115-123. (Pubitemid 38313727)
19. Düzova A, Kutluk T, Kanra G, et al. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr 2001;43:105-109. (Pubitemid 32537265)
20. Yildirim I, Aytac S, Ceyhan M, et al. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies. Pediatr Hematol Oncol 2008;25:291-299. (Pubitemid 351877035)
21. Corapcioglu F, Sarper N, Zengin E. Monotherapy with piperacillin/ tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: A randomized comparison. Pediatr Hematol Oncol 2006;23:177-186. (Pubitemid 43361800)
22. Le Guyader N, Auvrignon A, Vu-Thien H, et al. Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children. Support Care Cancer 2004;12:720-724. (Pubitemid 39362651)
23. Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: A systematic review and meta-analysis. Lancet Infect Dis 2007;7:338-348. (Pubitemid 46591956)
24. Towne TG, Lewis JS, Echevarria K. Efficacy and safety of cefepime. Lancet Infect Dis 2009;9:4-6.